Fraudulent Financial Statements in Mining Sector Companies Listed on the Bei for the Period 2018 – 2021
Journal Markcount Finance · 2023
DOI: 10.70177/jmf.v2i1.438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal Markcount Finance, 2023. Verfasst von Ngurah Pandji Mertha Agung Durya. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
This study aims to determine the effect of pressure, opportunity, rationalization, ability, arrogance, and Fraud Confirmation on financial statement fraud in mining sector companies listed on the Indonesia Stock Exchange in 2018-2021. The data used in this study are secondary data obtained from annual reports & reports. annual finance. By using purposive sampling technique, this study has a sample of 19 mining sector companies for 4 years, the observation data obtained is 76. The data analysis technique used is logistic regression analysis using SPSS 20 software. The results of this study indicate that the variables of pressure, opportunity, rationalization, the ability and arrogance to have no influence on fraudulent financial statements in mining sector companies listed on the Indonesia Stock Exchange in 2018-2021. Meanwhile, the variables of confirmation of fraud have an influence on fraudulent financial statements in mining sector companies listed on the Indonesia Stock Exchange in 2018-2021.
Zitieren
APA
Durya, N. P. M. A. (2023). Fraudulent Financial Statements in Mining Sector Companies Listed on the Bei for the Period 2018 – 2021. Journal Markcount Finance. https://doi.org/10.70177/jmf.v2i1.438
Vancouver
Durya NPMA. Fraudulent Financial Statements in Mining Sector Companies Listed on the Bei for the Period 2018 – 2021. Journal Markcount Finance. 2023. doi:10.70177/jmf.v2i1.438
BibTeX
@article{Durya2023,
author = {Durya, Ngurah Pandji Mertha Agung},
title = {Fraudulent Financial Statements in Mining Sector Companies Listed on the Bei for the Period 2018 – 2021},
journal = {Journal Markcount Finance},
year = {2023},
doi = {10.70177/jmf.v2i1.438}
}
EUVIMED